Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Elicio Therapeutics is a biotech company developing lymph node-targeted immunotherapies for cancer. Its proprietary AMP technology enhances T cell responses by delivering payloads to lymph nodes. The company’s focus includes off-the-shelf cancer vaccines targeting neoantigens like mutated KRAS, BRAF, and TP53, aiming to improve immune activation and treatment outcomes across various solid tumors. It collaborates with academic institutions and relies on third-party manufacturing.
This description was generated via AI from an annual report. Updated about 1 year ago.